June 20, 2022

Elevated Blood Counts May Factor in Thrombotic Events in Polycythemia Vera

Largest real-world cohort of polycythemia vera patients

22-CNR-2932808-CQD-Hero-650×450

A strong connection exists between elevated blood counts and increased thrombotic event risk in patients with polycythemia vera, according to research results presented at the 2022 European Hematology Association meeting.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A link between elevated hematocrit (red blood cell counts) and thrombosis has been long-established. As part of a nationwide study, researchers at Cleveland Clinic found that patients with elevated white blood cell count or platelet count also experienced higher incidents of thrombotic events such as blood clots, acute myocardial infarction and deep vein thrombosis. Notably, an elevated white count (>12) is significantly associated with increased risk of thrombotic events when hematocrit is controlled, indicating that risk factors may be reduced by controlling white blood cell count as well as hematocrit.

Identifying risk factors

Blood clots are a leading cause of morbidity and mortality in patients with polycythemia vera, yet there is still much to learn about the risk factors for these thrombotic events. “Just assessing risk based on age and prior history of blood clots is a very crude tool,” says study co-author Aaron T. Gerds, MD, MS, a staff physician with Cleveland Clinic Taussig Cancer Institute and Associate Professor of Medicine (Hematology and Medical Oncology) with the Cleveland Clinic Lerner College of Medicine. “Understanding what causes these patients to have blood clots is the first step in intervening on a deeper level to prevent clots from occurring.”

While the connection between thrombotic events and elevated hematocrit levels has been well documented, the association between higher platelet and white blood cell counts had not been evaluated in a consistent manner. Researchers sought to better understand these associations to develop more effective risk stratification.

To determine whether increased blood counts are predictive of thrombotic events, Dr. Gerds and his colleagues analyzed data from the REVEAL study, which is the largest prospective observational study about patients with polycythemia vera. They evaluated records for patients who had adequate numbers of blood counts recorded in the database. Of those 2,271 patients, 30 had arterial thrombotic events and 76 had venous thrombotic events. Among the 456 patients with a previous thrombotic event, 38 experienced another such event during follow-up.

Advertisement

“As the white blood cell count increases, we see increasing risk of blood clots,” says Dr. Gerds. “The association between elevated platelets is a little less clear. We did see an increased risk with elevated platelets, but when you raise the threshold to 600, there is no longer an association between platelet count and blood clot risk.”

Study methods

The association between blood count levels and thrombotic events was assessed using a time-dependent covariate Cox proportional hazards model. Time to first post-enrollment thrombotic event was modeled with follow-up time censored at last known visit for patients without a thrombotic event. Blood counts at the last lab test prior to thrombotic event or end of follow-up were included as binary time-dependent covariates using the established thresholds of hematocrit >45%, white blood cell count >11 and platelet count >400. Alternative thresholds of white blood cell count <7; ≥7 to <8.5, ≥8.5 to <11 ≥11 and platelet count >600 were also evaluated.

Under conditions where hematocrit was controlled, the association between white blood cell count elevation >11 did not quite reach significance. However, use of a higher white blood cell count threshold of >12 resulted in a significant association between elevated white blood cell count and thrombotic event risk.

The data supports the notion of incorporating blood count values into risk stratification and treatment strategies for patients with polycythemia vera.

Advertisement

Digging deeper

Dr. Gerds noted that this is the first step in a long process of data analysis. The researchers are now delving further into REVEAL study data to assess the relationship between thrombotic event risk and isolated white blood cell count elevation, as well as time-dependent risk with elevated blood count.

“We need to validate that elevated white blood cell count is a risk factor for thrombosis,” says Dr. Gerds. “And more importantly, we need to demonstrate that by lowering white blood cell count we can reverse the increased risk of thrombosis. Conversely, identifying those at lower risk may allow for the use of less aggressive treatments in those cases. Doing so would have a tremendous impact on clinical practice.”

Related Articles

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967&#215;544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

23-CNR-4318382-CQD-Hero-650&#215;450 Dr Hill
December 19, 2023
Active Surveillance may be a Feasible Option for a Subset of Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Large cohort study finds no reduction in survival for patients managed with active surveillance compared to treated patients

Dr. Caimi
December 15, 2023
CAR-T Cell Therapy Effective in Refractory Double-Hit/Triple-Hit Lymphoma

Two thirds of patients responded to CAR T-cell therapy

23-CNR-4344308-CQD-Hero-650&#215;450 Ornstein
December 14, 2023
Belzutifan Shows Improvement in Progression-Free Survival for Patients with Refractory Clear-Cell Kidney Cancer

Belzutifan superior to everolimus in phase 3 clinical trial

Ad